WEDNESDAY, Dec. 21, 2022 (HealthDay Information) — A bivalent booster mRNA vaccine dose is efficient in opposition to COVID-19-associated hospitalization in adults and seniors, in line with two research revealed within the Dec. 16 early-release situation of the U.S. Facilities for Illness Management and Prevention Morbidity and Mortality Weekly Report.
Mark W. Tenforde, M.D., Ph.D., from the CDC in Atlanta, and colleagues examined vaccine effectiveness (VE) of a bivalent mRNA booster dose (after two, three, or 4 monovalent doses) in contrast with no earlier vaccination or earlier receipt of two, three, or 4 monovalent-only mRNA vaccine doses amongst immunocompetent adults aged 18 years or older. The researchers discovered that the VE of a bivalent booster dose in opposition to COVID-19-associated emergency division/pressing care encounters was 56 % in contrast with no vaccination and 31 and 50 %, respectively, in contrast with monovalent vaccination solely with the final dose two to 4 or ≥11 months earlier. VE in opposition to COVID-19 related hospitalizations was 57 % in contrast with no vaccination and was 38 and 45 %, respectively, in contrast with monovalent vaccination solely with the final dose 5 to seven and ≥11 months earlier, respectively.
Diya Surie, M.D., additionally from the CDC, and colleagues examined the effectiveness of a bivalent booster dose obtained after two or extra doses of monovalent mRNA vaccine in opposition to COVID-19-associated hospitalizations amongst immunocompetent older adults (≥65 years). The researchers discovered that the VE of a bivalent booster dose obtained seven or extra days earlier than sickness onset in opposition to COVID-19-associated hospitalization was 84 % in contrast with unvaccinated individuals. The relative VE of a bivalent booster vaccine dose was 73 % in contrast with individuals who obtained two or extra monovalent-only mRNA vaccine doses.
“All eligible individuals, particularly adults aged ≥65 years, ought to obtain a bivalent booster dose to maximise safety in opposition to COVID-19 hospitalization this winter season,” Surie and colleagues write.
A number of authors from each research disclosed monetary ties to the pharmaceutical business.
